ORIC Pharmaceuticals, Inc. (ORIC) Cash Flow Statement

The persistent gap between net income and operating cash flow indicates that reported losses do not fully capture the cash-intensive nature of the firm's R&D activities. Investors should monitor the OCF/NI ratio closely, as the volatility in this metric suggests that timing differences in clinical trial payments and accruals are masking the underlying cash burn.

The lack of positive free cash flow is expected for a clinical-stage biotech, yet the consistency of these outflows highlights the company's total reliance on external financing. The absence of any trend toward FCF breakeven suggests that the firm's valuation remains entirely dependent on future clinical data readouts rather than operational efficiency.

These fluctuations likely reflect the lumpy nature of payments to clinical research organizations and the timing of vendor settlements. Such volatility in working capital suggests that the company's cash position is sensitive to operational timing, which may exacerbate liquidity pressures during periods of high clinical trial activity.